In the analyses by race and ethnicity, SGLT2 inhibitors appeared to have the most significant benefits on AF risk reduction in non-Hispanic White individuals (HR, 0.66; 95% CI, 0.51 to 0.86; p < 0.01). The gene discussed is SLC5A2; the disease is atrial fibrillation.